Japan Liver Cancer Therapeutics Market Report 2022 to 2030

Japan Liver Cancer Therapeutics Market Analysis

$ 3999

By 2030, it is anticipated that the Japan liver cancer therapeutics market will reach a value of $689.2 Mn from $182.12 Mn in 2022, growing at a CAGR of 18.1% during 2022-30. The liver cancer therapeutics market in Japan is dominated by a few domestic pharmaceutical companies such as Chugai Pharmaceutical, Taiho Pharmaceutical, and Eisai. The liver cancer therapeutics market in Japan is segmented into different types of cancer and different therapy type. Some of the major factors affecting this market are the growing prevalence of liver cancer and the high cost and side effects related to certain liver cancer therapies.

ID: IN10JPPH039 CATEGORY: Pharmaceuticals GEOGRAPHY: Japan AUTHOR: Dr. Vishwa Modhia

Buy Now

Japan Liver Cancer Therapeutics Analysis Summary

By 2030, it is anticipated that the Japan liver cancer therapeutics market will reach a value of $689.2 Mn from $182.12 Mn in 2022, growing at a CAGR of 18.1% during 2022-30.

Japan is a high-income developed island nation in East Asia. Hepatocellular carcinoma (HCC) is the main cause of cancer mortality in Japan, and HCV infection is a key cause of HCC. According to the most recent WHO data published in 2020, the number of people dying from liver cancer in Japan reached 29,384, accounting for 2.66 % of all deaths. Japan ranks 62nd in the world with an age-adjusted death rate of 6.62 per 100,000 inhabitants. In Japan, liver cancer is responsible for 21% of all gastrointestinal malignancies.

Because of the country's aging population and increased frequency of chronic diseases, Japan has relatively high per capita healthcare spending. Japan's government spent 10.3 % of its GDP on healthcare in 2020.

japan liver cancer therapeutics market

Market Dynamics

Market Growth Drivers

With an estimated 40,000 new cases identified each year, Japan has one of the highest rates of liver cancer in the world. As a result, there is an increasing demand for effective liver cancer treatments. The Japanese government reimburses for liver cancer therapies, which has encouraged patients to seek treatment and fueled market growth. Japan is fortunate to be located in a fast-expanding region. Japan offers cutting-edge technologies and a broad manufacturing sector.

Market Restraints

Japan's population is aging, which might increase the occurrence of liver cancer and make it difficult for healthcare providers to deliver high-quality care to a growing patient population. Liver cancer therapies can be costly, and the high expense of therapy may prevent some patients from receiving them. This might potentially place a load on the healthcare system and impede market expansion. Japan is dealing with a labor shortage and a low immigration contribution, which is increasing the proportion of insecure workers.

Competitive Landscape

Key Players

Chugai Pharmaceutical: Chugai is a Japanese pharmaceutical company that specializes in the development and manufacture of oncology drugs.
Taiho Pharmaceutical: Taiho is a Japanese pharmaceutical company that specializes in the development of oncology drugs. Their portfolio includes major drugs such as Lonsurf and Futibatinib
Eisai: Eisai is a Japanese pharmaceutical company that develops and manufactures drugs for various diseases, including cancer.
Ono Pharmaceutical: Ono is a Japanese pharmaceutical company that specializes in the development and manufacture of drugs for various diseases, including cancer.
Astellas Pharma

Recent Notable Updates

February 2023: Imfinzi (durvalumab) and Imjudo (tremelimumab) immunotherapy combinations from AstraZeneca have been licensed for the treatment of advanced liver and lung malignancies in Japan, the United States, China, and the European Union (EU).

Healthcare Policies and Reimbursement Scenarios

In Japan, the regulatory body responsible for the approval of liver cancer therapeutics is the Pharmaceuticals and Medical Devices Agency (PMDA). Once a medication is approved for use in Japan, it may be eligible for reimbursement under the National Health Insurance (NHI) program. The NHI program provides coverage for a wide range of medical services and medications, including those used in the treatment of liver cancer.

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Japan Liver Cancer Therapeutics Segmentation

By Type (Revenue, USD Billion):

Hepatocellular Carcinoma
Cholangio Carcinoma
Hepatoblastoma
Other Types

By Treatment (Revenue, USD Billion):

Chemotherapy
Immunotherapy
Targeted Therapy
Radiation Therapy
Ablation Therapy
Embolization Therapy

By Equipment (Revenue, USD Billion):

Computed Radiography
MRI
Sonography
Others

By Route of Administration (Revenue, USD Billion):

Oral
Intravenous

By End User (Revenue, USD Billion):

Hospitals
Clinics
Ambulatory Surgical Centers

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.